| 臺大學術典藏 |
2021-09-01T01:54:04Z |
Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells
|
Lin Y.-C.; Wu M.-H.; Wei T.-T.; Chung S.-H.; Chen K.-F.; ANN-LII CHENG; Chen C.-C. |
| 臺大學術典藏 |
2021-09-01T01:54:04Z |
Antiangiogenic strategies for the treatment of hepatocellular carcinoma
|
Hsu C.; Shen Y.-C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:04Z |
Asian consensus workshop report: Expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia
|
Han K.-H.; Kudo M.; Ye S.-L.; Choi J.Y.; Poon R.T.-P.; Seong J.; Park J.-W.; Ichida T.; Chung J.W.; Chow P.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:04Z |
T(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement
|
Kuo S.-H.; ANN-LII CHENG; Lin C.-W.; Hsu C.-H.; Wu M.-S.; Yeh K.-H.; Tzeng Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-09-01T01:54:05Z |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study
|
Ch'Ang H.-J.; Lin Y.-L.; Wang H.-P.; Chiu Y.-F.; Chang M.-C.; Hsu C.-H.; Tien Y.-W.; Chen J.-S.; Hsieh R.-K.; Lin P.-W.; Shan Y.-S.; ANN-LII CHENG; Chang J.-Y.; Whang-Peng J.; Hwang T.-L.; Chen L.-T. |
| 臺大學術典藏 |
2021-09-01T01:54:05Z |
Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era
|
Chen I.C.; Lin C.H.; Huang C.S.; Lien H.C.; Hsu C.; Kuo W.H.; Lu Y.S.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:05Z |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials
|
Yang S.-H.; Kuo Y.-H.; Tien Y.-W.; Hsu C.; Hsu C.-H.; Kuo S.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:06Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Shen Y.-C.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:06Z |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Hsu C.-Y.; Shen Y.-C.; Yu C.-W.; Hsu C.; Hu F.-C.; Hsu C.-H.; Chen B.-B.; Wei S.-Y.; ANN-LII CHENG; Shih T.T.-F. |
| 臺大學術典藏 |
2021-09-01T01:54:06Z |
Establishment of a novel MALT lymphoma cell line, ma-1, from a patient with t(14;18)(q32;q21)-positive Helicobacter Pylori-independent gastric MALT lymphoma
|
Kuo S.-H.; Weng W.-H.; Chen Z.-H.; Hsu P.-N.; Wu M.-S.; Lin C.-W.; Jeng H.-J.; Yeh K.-H.; Tsai H.-J.; Chen L.-T.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:07Z |
Prognostic molecular markers in Women aged 35 years or younger with breast cancer: Is there a difference from the older patients?
|
Lin C.-H.; Lu Y.-S.; Huang C.-S.; Kuo K.-T.; Wang C.-C.; You S.-L.; Lin P.-H.; Chang D.-Y.; Kuo W.-H.; Chang K.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:07Z |
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib
|
Harmon C.S.; DePrimo S.E.; Raymond E.; ANN-LII CHENG; Boucher E.; Douillard J.-Y.; Lim H.Y.; Kim J.S.; Lechuga M.J.; Lanzalone S.; Lin X.; Faivre S. |
| 臺大學術典藏 |
2021-09-01T01:54:07Z |
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib
|
Faivre S.; Zappa M.; Vilgrain V.; Boucher E.; Douillard J.-Y.; Lim H.Y.; Kim J.S.; Im S.-A.; Kang Y.-K.; Bouattour M.; Dokmak S.; Dreyer C.; Sablin M.-P.; Serrate C.; ANN-LII CHENG; Lanzalone S.; Lin X.; Lechuga M.J.; Raymond E. |
| 臺大學術典藏 |
2021-09-01T01:54:08Z |
A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan
|
Chen J.-S.; Chao Y.; Hsieh R.-K.; ANN-LII CHENG; Chen P.-M.; Chiou T.-J.; Chao T.-Y.; Yeh K.-H.; Chen L.-T.; Whang-Peng J. |
| 臺大學術典藏 |
2021-09-01T01:54:08Z |
Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cells
|
Rodriguez B.A.T.; Weng Y.-I.; Liu T.-M.; Zuo T.; Hsu P.-Y.; Lin C.-H.; ANN-LII CHENG; Cui H.; Yan P.S.; Huang T.H.-M. |
| 臺大學術典藏 |
2021-09-01T01:54:08Z |
IκB kinases increase Myc protein stability and enhance progression of breast cancer cells
|
Yeh P.-Y.; Lu Y.-S.; Ou D.-L.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:08Z |
Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001
|
Kuo S.-H.; Hsu C.-H.; Chen L.-T.; Lu Y.-S.; Lin C.-H.; Yeh P.-Y.; Jeng H.-J.; Gao M.; Yeh K.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:09Z |
Phase I, pharmacokinetic, and bone marrow drug-level studies of trimonthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers
|
Ho Y.-F.; Lu W.-C.; Chen R.R.-L.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:09Z |
Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma
|
Tai W.-T.; ANN-LII CHENG; Shiau C.-W.; Huang H.-P.; Huang J.-W.; Chen P.-J.; Chen K.-F. |
| 臺大學術典藏 |
2021-09-01T01:54:09Z |
Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapy
|
Shao Y.-Y.; Lu L.-C.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:10Z |
Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma
|
Shao Y.U.-Y.; Chen P.-J.; Lin Z.-Z.; Huang C.-C.; Ding Y.-H.; Lee Y.-H.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:10Z |
Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A
|
Chen K.-F.; Yu H.-C.; Liu C.-Y.; Chen H.-J.; Chen Y.-C.; Hou D.-R.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:10Z |
Needs for hepatocellular carcinoma control policy in the Asia-Pacific region
|
Bridges J.F.P.; Joy S..; Gallego G.; Kudo M.; Ye S.-L.; Han K.-H.; ANN-LII CHENG; Blauvelt B. |
| 臺大學術典藏 |
2021-09-01T01:54:10Z |
Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf
|
Chen K.-F.; Tai W.-T.; Huang J.-W.; Hsu C.-Y.; Chen W.-L.; ANN-LII CHENG; Chen P.-J.; Shiau C.-W. |
| 臺大學術典藏 |
2021-09-01T01:54:10Z |
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells
|
Chen K.-F.; Chen H.-L.; Tai W.-T.; Feng W.-C.; Hsu C.-H.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:11Z |
Recent advances in the treatment of metastatic colorectal cancer in Taiwan
|
Lin Y.-L.; Yeh K.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:11Z |
Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma
|
Chiang C.-T.; Yeh P.-Y.; Gao M.; Chen C.-W.; Yeh L.-C.; Feng W.-C.; Kuo S.-H.; Hsu C.-H.; Lu Y.-S.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:11Z |
CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells
|
Chen K.-F.; Liu C.-Y.; Lin Y.-C.; Yu H.-C.; Liu T.-H.; Hou D.-R.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:12Z |
Induction of DNA damage-inducible gene GADD45β contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells
|
Ou D.-L.; Shen Y.-C.; Yu S.-L.; Chen K.-F.; Yeh P.-Y.; Fan H.-H.; Feng W.-C.; Wang C.-T.; Lin L.-I.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:12Z |
E2A-positive gastric MALT lymphoma has weaker plasmacytoid infiltrates and stronger expression of the memory B-cell-associated miR-223: Possible correlation with stage and treatment response
|
Liu T.-Y.; Chen S.-U.; Kuo S.-H.; ANN-LII CHENG; Lin C.-W. |
| 臺大學術典藏 |
2021-09-01T01:54:12Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:12Z |
Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3
|
Chen K.-F.; Tai W.-T.; Liu T.-H.; Huang H.-P.; Lin Y.-C.; Shiau C.-W.; Li P.-K.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:13Z |
Epigenetic influences of low-dose bisphenol A in primary human breast epithelial cells
|
Weng Y.-I.; Hsu P.-Y.; Liyanarachchi S.; Liu J.; Deatherage D.E.; Huang Y.-W.; Zuo T.; Rodriguez B.; Lin C.-H.; ANN-LII CHENG; Huang T.H.-M. |
| 臺大學術典藏 |
2021-09-01T01:54:13Z |
Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC
|
Lin Z.-Z.; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Tsao H.-W.; Lai P.; Lee P.; ANN-LII CHENG; Hsu H.-C. |
| 臺大學術典藏 |
2021-09-01T01:54:13Z |
Liver cancer working group report
|
Kudo M.; Han K.H.; Kokudo N.; ANN-LII CHENG; Choi B.I.; Furuse J.; Izumi N.; Park J.-W.; Poon R.T.; Sakamoto M. |
| 臺大學術典藏 |
2021-09-01T01:54:13Z |
Translocation of Helicobacter pylori CagA into human B lymphocytes, the origin of mucosa-associated lymphoid tissue lymphoma
|
Lin W.-C.; Tsai H.-F.; Kuo S.-H.; Wu M.-S.; Lin C.-W.; Hsu P.-I.; ANN-LII CHENG; Hsu P.-N. |
| 臺大學術典藏 |
2021-09-01T01:54:14Z |
Vinorelbine plus 24-hour infusion of high-dose 5-fluorouracil and leucovorin as effective palliative chemotherapy for breast cancer patients with acute disseminated intravascular coagulation
|
Lin P.-H.; Lu Y.-S.; Lin C.-H.; Chang D.-Y.; Huang C.-S.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:14Z |
Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma
|
Whang-Peng J.; ANN-LII CHENG; Hsu C.; Chen C.-M. |
| 臺大學術典藏 |
2021-09-01T01:54:14Z |
O6-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers
|
Wu P.-F.; Kuo K.-T.; Kuo L.-T.; Lin Y.-T.; Lee W.-C.; Lu Y.-S.; Yang C.-H.; Wu R.-M.; Tu Y.-K.; Tasi J.-C.; Tseng H.-M.; Tseng S.-H.; ANN-LII CHENG; Lin C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:15Z |
Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach
|
Shen Y.-C.; Hsu C.; Chen L.-T.; Cheng C.-C.; Hu F.-C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:15Z |
Unusual presentation of multiple pathologic bone fractures in a patient with gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.; Yen R.-F.; Lin C.-W.; Chen L.-T.; Tien H.F.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:15Z |
The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells
|
Yan K.-H.; Yao C.-J.; Chang H.-Y.; Lai G.-M.; ANN-LII CHENG; Chuang S.-E. |
| 臺大學術典藏 |
2021-09-01T01:54:16Z |
Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation
|
Chen K.-F.; Yu H.-C.; Liu T.-H.; Lee S.-S.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:16Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:16Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
Shao Y.-Y.; Kuo K.-T.; Hu F.-C.; Lu Y.-S.; Huang C.-S.; Liau J.-Y.; Lee W.-C.; Hsu C.; Kuo W.-H.; Chang K.-J.; Lin C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:16Z |
Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma
|
Omata M.; Lesmana L.A.; Tateishi R.; Chen P.-J.; Lin S.-M.; Yoshida H.; Kudo M.; Lee J.M.; Choi B.I.; Poon R.T.P.; Shiina S.; ANN-LII CHENG; Jia J.-D.; Obi S.; Han K.H.; Jafri W.; Chow P.; Lim S.G.; Chawla Y.K.; Budihusodo U.; Gani R.A.; Lesmana C.R.; Putranto T.A.; Liaw Y.F.; Sarin S.K. |
| 臺大學術典藏 |
2021-09-01T01:54:17Z |
Molecular targeted therapy for advanced hepatocellular carcinoma: Current status and future perspectives
|
Shen Y.-C.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:17Z |
Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions
|
Shao Y.-Y.; Hu F.-C.; Liang J.-T.; Chiu W.-T.; ANN-LII CHENG; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:17Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Hsu C.-H.; Shen Y.-C.; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:18Z |
Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy
|
Lin C.-H.; Lien H.-C.; Hu F.-C.; Lu Y.-S.; Kuo S.-H.; Wu L.-C.; You S.-L.; ANN-LII CHENG; Chang K.-J.; Huang C.-S. |
